This Biotech Is Officially for Sale

Shares of small biotech firm Enzon (NASDAQ: ENZN  ) were up about 5% today after the CEO announced that Lazard had been hired to look into potentially selling some or all of the company. Carl Icahn, who has a 13% stake in the company, also met with management to discuss something similar; shares have been down since he announced that meeting in late November. In this video, Motley Fool health care analyst David Williamson tells investors what kind of influence we can expect Icahn to have on shares as the company moves toward selling.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 11, 2013, at 11:19 AM, rsinj wrote:

    And today it's hitting new 52-week lows.

    No buyout. No "strategic alternative". Anyone betting against Carl thus far has done well here.

Add your comment.

DocumentId: 2158590, ~/Articles/ArticleHandler.aspx, 7/24/2014 3:14:39 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement